PubMed for id: 8797

Year	Number of Results
1995	1
1997	7
1999	3
2000	3
2001	3
2002	9
2003	7
2004	14
2005	17
2006	12
2007	6
2008	16
2009	30
2010	23
2011	16
2012	18
2013	21
2014	14
2015	20
2016	9
2017	9
2018	10
2019	9
2020	5
2021	7
2023	1
2024	0

1

Genetic variations in tumor ecrosis factor related apoptosis-inducing ligand receptor-1 (TRAIL-R1) gene and the susceptibility to b-cell non-hodgkin lymphoma (B-NHL) in Egypt.

Khorshied M, Soliman N, Khorshid O, Bakr S. Khorshied M, et al. Cancer Biomark. 2021;32(4):451-458. doi: 10.3233/CBM-201786. Cancer Biomark. 2021. PMID: 34275891

2

O-glycans on death receptors in cells modulate their sensitivity to TRAIL-induced apoptosis through affecting on their stability and oligomerization.

Jiang Y, Wen T, Yan R, Kim SR, Stowell SR, Wang W, Wang Y, An G, Cummings RD, Ju T. Jiang Y, et al. FASEB J. 2020 Sep;34(9):11786-11801. doi: 10.1096/fj.201900053RR. Epub 2020 Jul 21. FASEB J. 2020. PMID: 32692906

3

TNF-Related Apoptosis-Inducing Ligand Receptor 1 in Patients With Ankylosing Spondylitis.

Karadag DT, Tekeoglu S, Yazici A, Isik OO, Eraldemir FC, Cefle A. Karadag DT, et al. J Clin Rheumatol. 2020 Sep;26(6):242-247. doi: 10.1097/RHU.0000000000001050. J Clin Rheumatol. 2020. PMID: 31094932

4

DR4-Ser424 O-GlcNAcylation Promotes Sensitization of TRAIL-Tolerant Persisters and TRAIL-Resistant Cancer Cells to Death.

Lee H, Oh Y, Jeon YJ, Lee SY, Kim H, Lee HJ, Jung YK. Lee H, et al. Cancer Res. 2019 Jun 1;79(11):2839-2852. doi: 10.1158/0008-5472.CAN-18-1991. Epub 2019 Apr 15. Cancer Res. 2019. PMID: 30987996

5

Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma.

Zayed SA, Zahran NM, Khorshied MM, Abdel-Aziz AO, Mahmoud O, Morsy SA, Shousha HI, Elbaz TM, Nabeel MM, Harb ARK. Zayed SA, et al. J Med Virol. 2019 Aug;91(8):1537-1544. doi: 10.1002/jmv.25476. Epub 2019 Apr 25. J Med Virol. 2019. PMID: 30945308

6

The impact of TRAIL on proliferation of secretory prostate cancer PC-3 cell and LMO2 gene expression.

Che Z, Li HW, Wang P, Jiang B, Li B, Zhao K, Wang SP, Gao H, Zhang MQ. Che Z, et al. Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7172-7177. doi: 10.26355/eurrev_201811_16249. Eur Rev Med Pharmacol Sci. 2018. PMID: 30468458 Free article.

7

Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC.

Gundlach JP, Hauser C, Schlegel FM, Böger C, Röder C, Röcken C, Becker T, Egberts JH, Kalthoff H, Trauzold A. Gundlach JP, et al. BMC Cancer. 2018 Jul 31;18(1):777. doi: 10.1186/s12885-018-4688-8. BMC Cancer. 2018. PMID: 30064384 Free PMC article.

8

DR4 mediates the progression, invasion, metastasis and survival of colorectal cancer through the Sp1/NF1 switch axis on genomic locus.

Wu S, Meng Q, Zhang C, Sun H, Lu R, Gao N, Yang H, Li X, Aschner M, Chen R. Wu S, et al. Int J Cancer. 2018 Jul 15;143(2):289-297. doi: 10.1002/ijc.31318. Epub 2018 Mar 1. Int J Cancer. 2018. PMID: 29446085 Free article.

9

Evaluation of serum trail level and DR4 gene variants as biomarkers for vitiligo patients.

Edgunlu T, Solak Tekin N, Ozel Turkcu Ü, Karakaş-Çelik S, Urhan-Kucuk M, Tekin L. Edgunlu T, et al. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):e97-e98. doi: 10.1111/jdv.13340. Epub 2015 Sep 25. J Eur Acad Dermatol Venereol. 2016. PMID: 26404509 No abstract available.

10

Genetic association between TRAIL-R1 Thr209Arg and cancer susceptibility.

Geng P, Li J, Wang N, Liao Y, Ou J, Sa R, Xie G, Liu C, Li H, Xiang L, Liang H. Geng P, et al. Sci Rep. 2015 Aug 28;5:10382. doi: 10.1038/srep10382. Sci Rep. 2015. PMID: 26315998 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

265 results

Results by year